Artiva Biotherapeutics, Inc. ARTV 深 沪
等待开盘 03-27 09:30:00 美东时间
5.16
-0.300
-5.49%
华盛通- 最 高7.7542
- 今 开5.42
- 成交量 10.49万股
- 最 低 5.08
- 昨 收 5.46
- 总市值 0
- 52周最高 7.7542
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 1.47
- 委 比 98.26%
- 总股本 --
- 历史最高 17.305
- 量 比 1.30
- 振 幅 48.98%
- 历史最低 1.47
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artiva Biotherapeutics Appoints Thad Huston CFO,
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and
02-24 21:02
US Stocks Mixed; NY Manufacturing Activity Dips In December
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around ...
2025-12-15 23:02
亚洲权威消费科技与室内设计盛会 "设计深圳"2025将于9月盛大开展
深圳2025年8月4日 /美通社/ --第三届"设计深圳Design Shenzhen"将于2025年9月18日至21日在深圳会展中心举办。作为亚洲...
2025-08-04 20:14
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
Artiva Biotherapeutics announced its participation in the Jefferies Global Healthcare Conference with a fireside chat and investor meetings. The company focuses on developing cell therapies for autoimmune diseases and cancers, particularly through its AlloNK® program targeting B-cell driven conditions. Artiva was founded in 2019 as a spinout from GC Cell, leveraging its NK cell manufacturing technology.
2025-05-28 20:05
Artiva Biotherapeutics Reports Wider Q2 Loss, No Revenue
05:31 PM EDT, 08/29/2024 (MT Newswires) -- Artiva Biotherapeutics (ARTV) reported a Q2 loss late Thursday of $22 per diluted share, wider than a loss of $14.09 a year earlier. Four analysts surveyed by Capital IQ expected a loss of $4.40. No revenue for the quarter ended June 30 was reported. Revenu...
2024-08-30 05:31
Artiva Biotherapeutics Q2 EPS $(22.00) Down From $(14.09) YoY
Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(22.00) per share. This is a 56.14 percent decrease over losses of $(14.09) per share from the same period last year.
2024-08-30 04:14
